the lessened cardiotoxicity of epirubicin versus doxorubicin can be explained by the different pharmacokinetic and metabolic properties of these two agents : epirubicin has been found to have a more rapid pharmacokinetic plasma clearance and an additional metabolic pathway ( unique glucuronidation ) .
C0013089
doxorubicin
C0014582
epirubicin